INSMED INC (INSM) Stock Price, Quote, News and Overview
NASDAQ:INSM - Nasdaq - US4576693075 - Common Stock - Currency: USD
INSM Quote, Performance and Key Statistics
109.55
+0.25 (+0.23%)
The current stock price of INSM is 109.55 USD. In the past month the price increased by 11.58%. In the past year, price increased by 48.08%.
INSM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.7 | 349.84B | ||
| AMGN | AMGEN INC | 13.22 | 154.98B | ||
| GILD | GILEAD SCIENCES INC | 15.43 | 148.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.64 | 94.13B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 60.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 57.23B | ||
| ARGX | ARGENX SE - ADR | 71.39 | 40.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.5 | 31.19B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.84B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.28B | ||
| NTRA | NATERA INC | N/A | 20.75B | ||
| BIIB | BIOGEN INC | 8.16 | 19.15B |
Related stock screener links
About INSM
Company Profile
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 1,271 full-time employees. The firm is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.
Company Info
INSMED INC
700 Us Highway 202/206
Bridgewater NEW JERSEY 08807 US
CEO: William H. Lewis
Employees: 1271
Phone: 19089779900
INSMED INC / INSM FAQ
What is the stock price of INSMED INC today?
The current stock price of INSM is 109.55 USD. The price increased by 0.23% in the last trading session.
What is the ticker symbol for INSMED INC stock?
The exchange symbol of INSMED INC is INSM and it is listed on the Nasdaq exchange.
On which exchange is INSM stock listed?
INSM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INSMED INC stock?
25 analysts have analysed INSM and the average price target is 117.89 USD. This implies a price increase of 7.62% is expected in the next year compared to the current price of 109.55. Check the INSMED INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INSMED INC worth?
INSMED INC (INSM) has a market capitalization of 20.78B USD. This makes INSM a Large Cap stock.
How many employees does INSMED INC have?
INSMED INC (INSM) currently has 1271 employees.
What are the support and resistance levels for INSMED INC (INSM) stock?
INSMED INC (INSM) has a support level at 105.68 and a resistance level at 109.56. Check the full technical report for a detailed analysis of INSM support and resistance levels.
Is INSMED INC (INSM) expected to grow?
The Revenue of INSMED INC (INSM) is expected to grow by 26.22% in the next year. Check the estimates tab for more information on the INSM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INSMED INC (INSM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INSM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INSM, evaluating the profitability, health, valuation and growth aspects
- INSMED INC (INSM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INSMED INC (INSM) Sales and EPS estimates to see what analysts future expectations are.
- INSMED INC (INSM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INSMED INC (INSM) Insider and Institutional Ownership to learn about the owners and their transactions.
- INSMED INC (INSM) Stock Chart to make your own analysis
- INSMED INC (INSM) Latest news and press-releases to stay up to date.
Does INSMED INC (INSM) stock pay dividends?
INSM does not pay a dividend.
When does INSMED INC (INSM) report earnings?
INSMED INC (INSM) will report earnings on 2025-10-29.
What is the Price/Earnings (PE) ratio of INSMED INC (INSM)?
INSMED INC (INSM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.95).
What is the Short Interest ratio of INSMED INC (INSM) stock?
The outstanding short interest for INSMED INC (INSM) is 5.17% of its float. Check the ownership tab for more information on the INSM short interest.
INSM Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to INSM. When comparing the yearly performance of all stocks, INSM is one of the better performing stocks in the market, outperforming 93.12% of all stocks.
INSM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to INSM. The financial health of INSM is average, but there are quite some concerns on its profitability.
INSM Financial Highlights
Over the last trailing twelve months INSM reported a non-GAAP Earnings per Share(EPS) of -5.95. The EPS decreased by -13.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.21% | ||
| ROE | -1021.86% | ||
| Debt/Equity | 11.38 |
INSM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to INSM. The Buy consensus is the average rating of analysts ratings from 25 analysts.
For the next year, analysts expect an EPS growth of 3.39% and a revenue growth 26.22% for INSM